Helix BioPharma Corp. is experiencing a downturn as its stock drops significantly in today's trading session.
Helix BioPharma Corp. (HBP.TO) has seen its stock price decline by 4.05% today, closing at CA$1.42. This drop comes amidst a lack of significant news that could have positively influenced investor sentiment.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$114.57M
52W high
$5.40
52W low
$0.98
1W change
+2.07%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 68.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+68.9% Upside
Current Price
C$1.48
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
48.7%
Annualized
90-Day Vol
65.6%
Annualized
Trend (90d)
-43.1%
Annualized drift
90d Mean
C$1.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.19 – C$1.66 |
| 60 trading days | C$1.34 | C$1.05 – C$1.69 |
| 90 trading days | C$1.27 | C$0.95 – C$1.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious with Helix BioPharma as the stock's recent performance indicates potential volatility and uncertainty in its market position.
Stock Down 4.05% Today
With a market cap of CA$114.57 million, Helix BioPharma's stock performance is critical for maintaining investor interest and confidence.
Bull case
If Helix BioPharma can successfully navigate its ongoing fundraising efforts and secure institutional investment, it may regain investor confidence and stabilize its stock price.
Bear case
Continued financial struggles and a lack of substantial news could lead to further declines in stock value, making it a risky investment right now.
Market Reaction
Advertisement
The market's reaction to Helix BioPharma's stock today reflects broader investor sentiment, especially in the biotech sector. The 4.05% decrease raises questions about the company's future prospects and its ability to attract new investments.
Investor Sentiment
With no major announcements or developments from Helix BioPharma, investor sentiment seems cautious. The absence of positive news may have contributed to today's stock slide, prompting some investors to reconsider their positions. For more details, visit the Helix BioPharma stock page.
Looking Ahead
As Helix BioPharma navigates its current challenges, investors will be closely monitoring any upcoming announcements or financial results. The company's ability to stabilize its stock price will depend on its strategic moves in the coming weeks. For ongoing updates, check the latest news on Helix BioPharma.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
